Physician profile
John C Rabine
NPI 1114912631
$8,278.07
in general payments reported to CMS, 2019-2025
44 companies · $1,851 in 2025
The $1,851 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,220 · 2020: $480 · 2021: $816 · 2022: $955 · 2023: $1,536 · 2024: $1,420 · 2025: $1,851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,806.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,520.93 | 2019-2025 | |
| Janssen Biotech, INC. | $750.05 | 2019-2025 | Tremfya, Stelara, Simponi |
| Boston Scientific Corporation | $624.45 | 2020-2025 | Exalt Model D, Overstitch Endoscopic Suturing System, Axios |
| Covidien LP | $545.39 | 2019 | |
| Pfizer INC. | $479.37 | 2019-2025 | |
| Gilead Sciences, INC. | $452.83 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $386.66 | 2019-2025 | Entyvio, Gattex, Vpriv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $317.43 | 2019-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $245.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $183.28 | 2024-2025 | Zenpep, Vowst |
| Merck Sharp & Dohme LLC | $173.59 | 2019-2023 | Dificid |
| Nestle Healthcare Nutrition INC. | $134.68 | 2021-2023 | |
| Celgene Corporation | $112.89 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $110.54 | 2023-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $100.96 | 2023-2025 | Terlivaz |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $94.50 | 2021 | |
| Ferring Pharmaceuticals INC. | $86.61 | 2019-2024 | Rebyota |
| Echosens North America, INC. | $82.93 | 2023 | Fibroscan |
| Ipsen Biopharmaceuticals, INC | $72.46 | 2024-2025 | Iqirvo, Bylvay |
| Qol Medical, LLC | $60.05 | 2021-2023 | Sucraid |
| Phathom Pharmaceuticals, INC. | $57.51 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $56.10 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $54.69 | 2021 | |
| Amgen INC. | $53.05 | 2023 | Avsola, Amjevita |
| Redhill Biopharma INC. | $51.41 | 2020-2022 | |
| Sandoz INC. | $49.59 | 2023-2024 | Hyrimoz |
| Shionogi INC | $43.82 | 2019 | |
| Organon LLC | $42.58 | 2023-2024 | Renflexis, Hadlima |
| Braintree Laboratories, INC. | $39.82 | 2020-2023 | Sutab |
| Medtronic, INC. | $37.07 | 2023-2024 | Gi Genius, Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.08 | 2023-2024 | Cyltezo, Jardiance |
| Daiichi Sankyo INC. | $29.13 | 2024 | Injectafer |
| Digestive Care, INC. | $22.57 | 2025 | Pertzye |
| Shire North American Group INC | $19.53 | 2019 | |
| Alnylam Pharmaceuticals INC. | $19.34 | 2023 | Givlaari |
| Dynavax Technologies Corporation | $17.12 | 2025 | Heplisav-B |
| Merit Medical Systems INC | $16.52 | 2024 | Big60 Inflation Device |
| Evoke Pharma, INC. | $16.43 | 2024 | |
| Ucb, INC. | $14.67 | 2019 | |
| W. L. Gore & Associates, INC. | $14.60 | 2023 | Gore Cardioform Septal Occluder |
| Celltrion USA INC. | $14.51 | 2025 | Vegzelma |
| Ambu INC. | $13.56 | 2021 | |
| Allergan, INC. | $13.12 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rabine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.